|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High levels of CD163-positive macrophages were associated with BVI and lymphatic involvement as well as interval cancer detection when compared to screening-detected tumors.
|
28923419 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This represents the first report investigating the tumor immune microenvironment as a prognostic factor in synovial sarcoma, indicating that CD163+ macrophages are associated with tumor progression.
|
30133055 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CD163 staining was performed on the primary tumor, a negative draining lymph node, and a level four lymph node with a focus of metastatic prostate cancer and compared to benign controls.
|
28716144 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Patients with CD163-positive tumors and strong MI had significantly longer cancer-specific survival (CSS) (76 months), compared to patient with CD163-positive tumors and weak MI (28 months) (P = 0.02).
|
29288002 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The number of CD68-positive cells in the tumor microenvironment did not exhibit significant prognostic value, whereas higher number of CD163-positive cells was associated with inferior overall survival in patients treated with chemotherapy alone.
|
30106758 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To better understand the correlation between BRCA1/2 mutations and the immune phenotype in prostate cancer, we characterized the immune infiltrate of eight BRCA2-mutated tumors in comparison with eight BRCA1/2 wild-type patients by T-cell receptor sequencing and immunohistochemistry for CD45, CD4, CD8, FOXP3, and CD163.
|
31549213 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor microenvironment, including tumor-associated macrophages, may play a role in the transition from in situ to invasive carcinoma, and the presence of CD163-positive cells with DCIS has been associated with increased risk of progression to invasive carcinoma.
|
30067949 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We also analyzed the infiltration of CD68- and CD163-positive macrophages in tumor tissue of AITL.
|
29100307 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The increased number of CD163-positive TAMs in tumor nest and tumor stromal was positively associated with Kazakh ESCC lymph node metastasis and clinical stage progression.
|
27939650 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor-associated macrophages in oral premalignant lesions coexpress CD163 and STAT1 in a Th1-dominated microenvironment.
|
26242181 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CD68 + CD163- M1 macrophages and CD68 + CD163+ M2 macrophages were analyzed in ten high power fields sparing macrophage-poor areas and a mean value was calculated for each tumor.
|
23206928 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Patients underwent tumor biopsies at baseline and after cycle 2 for GE profiling and enumeration of TIL, FOXP3+ T-cells and CD163+ macrophages.
|
30228933 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We evaluated PD-L1 expression on TCs and ICs using Ventana SP263 assay and the stromal M2 TAM distribution using CD163 staining in 160 consecutive patients with resected non-small cell lung cancer (NSCLC).
|
31499335 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tumor characterization allowed us to identify a positive correlation between CCL4 and the pro-tumor macrophages marker CD163 ( p = 0.0443), and a negative correlation of iNOS with desmoplastic reaction ( p = 0.0467).
|
30419802 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor-promoting macrophages induce the expression of the macrophage-specific receptor CD163 in malignant cells.
|
22362417 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CD163, which marks tumor associated microglia/macrophages (TAMs), showed the highest expression level in GBM patients.
|
30375429 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Five cases of HS were studied to further elucidate the clinicopathologic features of these rare tumors and to demonstrate the diagnostic utility of CD163.
|
15696128 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We found that the co-culture of skin cells and CD163 overexpressing macrophages reduced monocyte chemoattractant protein (MCP)-1 and enhanced tumor growth factor (TGF)-α, without altering interleukin (IL)-6 or TGF-β.
|
31711674 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, the density of CD163+ TAMs correlated with tumor infiltrating lymphocytes (TILs).
|
26714314 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High numbers of non-HRS cells expressing CSF-1R were significantly associated with a high number of tumor-associated macrophages as detected by CD163 expression (P < .001).
|
24619759 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PD-L1 tumor expression was assessed using immunohistochemistry with two antibodies (clones 5H1 and E1L3N), and tumor immune-cell infiltration with CD3, CD4, CD8, CD20, CD163, and MPO.
|
29194117 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Most TAMs were located in the tumor stroma (>95%) and positively costained with the M2 marker CD163.
|
22174092 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Prognostic Impact of CD163+ Macrophages in Tumor Stroma and CD8+ T-Cells in Cancer Cell Nests in Invasive Extrahepatic Bile Duct Cancer.
|
28011489 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The expression levels of PFKFB3, CD163 and CD31 were significantly increased in OSCC specimens as compared with normal oral mucosa (P<0.05), and PFKFB was signifcantly correlated with tumor differentiation and tumor size (P<0.05), and CD163 was significantly correlated with areca nut chewing habit among OSCC tissues (P<0.05).
|
31209811 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CD68+ and CD163+ TAMs were seen within the tumor in all 35 specimens; their density was "moderate" in 50% of cases and "few" in 43%, and the majority showed an "indeterminate" phenotype.
|
28655639 |
2017 |